The Past, Present, and Future of Chemical Risk Assessment

Methods in Pharmacology and Toxicology

Volumn 2014, Issue , 2014, Pages 3-22

  Limonciel, Alice ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alternative to animal experimentation; Animal free; Chemical risk assessment; In vitro test systems; Systems toxicology; Toxicity testing

Indexed keywords

EID: 84930758789     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0521-8_1     Document Type: Chapter

References (61)

1. Russell WMS, Burch RL (1959) The principles of humane experimental technique. Methuen, London
2. Leist M, Hartung T (2013) Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol 87(4): 563–567. doi:10.1007/s00204-013-1038-0
3. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1): 56–67. doi:10.1006/rtph.2000.1399
4. Blaauboer BJ, Boekelheide K, Clewell HJ, Daneshian M, Dingemans MM, Goldberg AM, Heneweer M, Jaworska J, Kramer NI, Leist M, Seibert H, Testai E, Vandebriel RJ, Yager JD, Zurlo J (2012) The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX 29(4):411–425
5. Klimisch HJ (1993) Lung deposition, lung clearance and renal accumulation of inhaled cadmium chloride and cadmium sulphide in rats. Toxicology 84(1–3):103–124
6. IARC (1997) Monographs on the evaluation of carcinogenic risks to humans. Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry, vol 58. IARC, Lyon
7. Wilmes A, Crean D, Aydin S, Pfaller W, Jennings P, Leonard MO (2011) Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol In Vitro 25(3):613–622. doi:10.1016/j.tiv.2010.12.009
8. Hahn H, Huck CW, Rainer M, Najam-ul-Haq M, Bakry R, Abberger T, Jennings P, Pfaller W, Bonn GK (2007) Analysis of glutathione in supernatants and lysates of a human proximal tubular cell line from perfusion culture upon intoxication with cadmium chloride by HPLC and LC-ESI-MS. Anal Bioanal Chem 388(8):1763–1769. doi:10.1007/s00216-007-1401-1
9. Forti E, Bulgheroni A, Cetin Y, Hartung T, Jennings P, Pfaller W, Prieto P (2010) Characterisation of cadmium chloride induced molecular and functional alterations in airway epithelial cells. Cell Physiol Biochem 25(1):159–168. doi:10.1159/000272060
10. Campbell KC (2006) Bromate-induced ototoxicity. Toxicology 221(2–3):205–211. doi:10.1016/j.tox.2005.12.015
11. DeAngelo AB, George MH, Kilburn SR, Moore TM, Wolf DC (1998) Carcinogenicity of potassium bromate administered in the drinking water to male B6C3F1 mice and F344/N rats. Toxicol Pathol 26(5):587–594
12. Kurokawa Y, Aoki S, Matsushima Y, Takamura N, Imazawa T, Hayashi Y (1986) Dose-response studies on the carcinogenicity of potassium bromate in F344 rats after long-term oral administration. J Natl Cancer Inst 77(4):977–982
13. Cho DH, Hong JT, Chin K, Cho TS, Lee BM (1993) Organotropic formation and disappearance of 8-hydroxydeoxyguanosine in the kidney of Sprague-Dawley rats exposed to adriamycin and KBrO3. Cancer Lett 74(3):141–145
14. Fujie K, Shimazu H, Matsuda M, Sugiyama T (1988) Acute cytogenetic effects of potassium bromate on rat bone marrow cells in vivo. Mutat Res 206(4):455–458
15. Hayashi M, Kishi M, Sofuni T, Ishidate M Jr (1988) Micronucleus tests in mice on 39 food additives and eight miscellaneous chemicals. Food Chem Toxicol 26(6):487–500
16. Limonciel A, Wilmes A, Aschauer L, Radford R, Bloch KM, McMorrow T, Pfaller W, van Delft JH, Slattery C, Ryan MP, Lock EA, Jennings P (2012) Oxidative stress induced by potassium bromate exposure results in altered tight junction protein expression in renal proximal tubule cells. Arch Toxicol 86(11):1741– 1751. doi:10.1007/s00204-012-0897-0
17. Boorman GA, McDonald MR, Imoto S, Persing R (1992) Renal lesions induced by Ochratoxin A exposure in the F344 rat. Toxicol Pathol 20(2):236–245
18. NTP (1989) Toxicology and carcinogenesis studies of Ochratoxin A (CAS No. 303-47-9) in F344/N Rats (gavage studies). National Toxicology Program Technical Report Series 358:1–142
19. Jennings P, Weiland C, Limonciel A, Bloch KM, Radford R, Aschauer L, McMorrow T, Wilmes A, Pfaller W, Ahr HJ, Slattery C, Lock EA, Ryan MP, Ellinger-Ziegelbauer H (2012) Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model. Arch Toxicol 86(4):571–589. doi:10.1007/s00204-011-0780-4
20. JRC (2013) http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/validation-regulator y-acceptance. Accessed 12 July 2013
21. Essack SY (2001) The development of beta-lactam antibiotics in response to the evolution of beta-lactamases. Pharm Res 18(10):1391–1399
22. Kahan BD (2011) Fifty years in the vineyard of transplantation: looking back. Transplant Proc 43(8):2853–2859. doi:10.1016/j.transpro-ceed. 2011.08.058
23. Lombardino JG, Lowe JA 3rd (2004) The role of the medicinal chemist in drug discovery— then and now. Nat Rev Drug Discov 3(10):853–862. doi:10.1038/nrd1523
24. Ballentine C (1981) Taste of raspberries, taste of death. The 1937 Elixir Sulfanilamide Incident. FDA Consumer Magazine. FDA
25. Von Oettingen WF, Jirouch EA (1931) The pharmacology of ethylene glycol and some of its derivatives in relation to their chemical constitution and physical chemical properties. J Pharmacol Exp Ther 42:355–372
26. Haag HB, Ambrose AM (1937) Studies on the physiological effect of diethylene glycol. II Toxicity and fate. J Pharmacol Exp Ther 59: 93–100
27. Nicholls AG (1937) The elixir sulfanilamide-massengill. Can Med Assoc J 37(6):590
28. FDA (2012) FDA history—part II. The 1938 food, drug, and cosmetic act. http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054826.htm. Accessed 17 June 2013
29. Emanuel M, Rawlins M, Duff G, Brecke-nridge A (2012) Thalidomide and its sequelae. Lancet 380(9844):781–783. doi:10.1016/S0140-6736(12)60468-1
30. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 278(7216):1358. doi:10.1016/S0140-6736(61)90927-8
31. Syme MR, Paxton JW, Keelan JA (2004) Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43(8): 487–514
32. Kim JH, Scialli AR (2011) Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122(1):1–6. doi:10.1093/toxsci/kfr088
33. Rägo L, Santoso B (2008) Drug regulation: history, present and future. In: van Boxtel CJ, Santoso B, Edwards IR (eds) WHO drug benefits and risks: international textbook of clinical pharmacology. IOS Press and Uppsala Monitoring Centre, Amsterdam
34. ECVAM (2013) Acute toxicity. http://ihcp. j r c. ec. eur opa. eu/our _l abs/eur l-ecvam/validation-regulator y-acceptance/systemic-toxicity/acute-toxicity. Accessed 30 July 2013
35. Trevan JW (1927) The error of determination of toxicity. Proc R Soc Lond B 101:483–514
36. Gribaldo L, Gennari A, Blackburn K, Clemedson C, Deguercy A, Meneguz A, Pfaller W, Ruhdel I (2005) Acute toxicity. Altern Lab Anim 33(Suppl 1):27–34
37. Schlede E, Genschow E, Spielmann H, Stropp G, Kayser D (2005) Oral acute toxic class method: a successful alternative to the oral LD50 test. Regul Toxicol Pharmacol 42(1): 15–23. doi:10.1016/j.yrtph.2004.12.006
38. Lipnick RL, Cotruvo JA, Hill RN, Bruce RD, Stitzel KA, Walker AP, Chu I, Goddard M, Segal L, Springer JA, Myers RC (1995) Comparison of the up-and-down, conventional Ld(50), and fixed-dose acute toxicity procedures. Food Chem Toxicol 33(3):223–231. doi:10.1016/0278-6915(94)00136-C
39. Bruce RD (1985) An up-and-down procedure for acute toxicity testing. Fundam Appl Toxicol 5(1):151–157
40. Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, Lampo A, Nahas K, Nogues V, Ockert D, Quinn K, Old S, Pickersgill N, Somers K, Stark C, Stei P, Waterson L, Chapman K (2008) A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul Toxicol Pharmacol 50(3):345–352. doi:10.1016/j.yrtph.2007.11.009
41. EMA (2010) Questions and answers on the withdrawal of the ‘Note for guidance on single dose toxicity’ EMA/CHMP/SWP/81714/ 2010
42. Prieto P, Baird AW, Blaauboer BJ, Castell Ripoll JV, Corvi R, Dekant W, Dietl P, Gennari A, Gribaldo L, Griffin JL, Hartung T, Heindel JJ, Hoet P, Jennings P, Marocchio L, Noraberg J, Pazos P, Westmoreland C, Wolf A, Wright J, Pfaller W (2006) The assessment of repeated dose toxicity in vitro: a proposed approach. The report and recommendations of ECVAM workshop 56. Altern Lab Anim 34(3):315–341
43. Renwick AG, Lazarus NR (1998) Human variability and noncancer risk assessment—an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 27(1 Pt 1):3–20
44. Hengstler JG, Marchan R, Leist M (2012) Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing. Arch Toxicol 86(1):13–15. doi:10.1007/s00204-011-0798-7
45. EMA (2010) Repeated dose toxicity. CPMP/ SWP/1042/99 Rev. 1 Corr
46. Knight A (2008) Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Rev Recent Clin Trials 3(2):89–96
47. Preziosi P (2004) Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nat Rev Drug Discov 3(6):521–526. doi:10.1038/nrd1418
48. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203–214. doi:10.1038/nrd3078
49. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–715. doi:10.1038/nrd1470
50. Balls M (2004) Are animal tests inherently valid? Altern Lab Anim 32(Suppl 1):755–758
51. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10): 1018–1028. doi:10.1056/NEJMoa063842
52. Stebbings R, Poole S, Thorpe R (2009) Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20(6):673–677. doi:10.1016/j.copbio.2009.10.002
53. van der Valk J, Brunner D, De Smet K, Fex Svenningsen A, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G (2010) Optimization of chemically defined cell culture media—replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro 24(4):1053–1063. doi:10.1016/j.tiv.2010.03.016
54. EC (2013) Full EU ban on animal testing for cosmetics enters into force. http://europa.eu/rapid/press-release_IP-13-210_en.htm
55. Limonciel A, Aschauer L, Wilmes A, Prajczer S, Leonard MO, Pfaller W, Jennings P (2011) Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. Toxicol In Vitro 25(8):1855–1862. doi:10.1016/j. tiv.2011.05.018
56. Wilmes A, Limonciel A, Aschauer L, Moenks K, Bielow C, Leonard MO, Hamon J, Carpi D, Ruzek S, Handler A, Schmal O, Herrgen K, Bellwon P, Burek C, Truisi GL, Hewitt P, Di Consiglio E, Testai E, Blaauboer BJ, Guillou C, Huber CG, Lukas A, Pfaller W, Mueller SO, Bois FY, Dekant W, Jennings P (2013) Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics 79:180–194. doi:10.1016/j. jprot.2012.11.022
57. Hartung T, van Vliet E, Jaworska J, Bonilla L, Skinner N, Thomas R (2012) Systems toxicology. ALTEX 29(2):119–128
58. Yamada F, Sumida K, Uehara T, Morikawa Y, Yamada H, Urushidani T, Ohno Y (2012) Toxicogenomics discrimination of potential hepatocarcinogenicity of non-genotoxic compounds in rat liver. J Appl Toxicol. doi:10.1002/jat.2790
59. Doktorova TY, Yildirimman R, Vinken M, Vilardell M, Vanhaecke T, Gmuender H, Bort R, Brolen G, Holmgren G, Li R, Chesne C, van Delft J, Kleinjans J, Castell J, Bjorquist P, Herwig R, Rogiers V (2013) Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Carcinogenesis 34:1393. doi:10.1093/carcin/bgt054
60. Jennen D, Ruiz-Aracama A, Magkoufopoulou C, Peijnenburg A, Lommen A, van Delft J, Kleinjans J (2011) Integrating transcriptomics and metabonomics to unravel modes-of-action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells. BMC Syst Biol 5:139. doi:10.1186/1752-0509-5-139
61. Jetten MJ, Gaj S, Ruiz-Aracama A, de Kok TM, van Delft JH, Lommen A, van Someren EP, Jennen DG, Claessen SM, Peijnenburg AA, Stierum RH, Kleinjans JC (2012) Omics analysis of low dose acetaminophen intake demonstrates novel response pathways in humans. Toxicol Appl Pharmacol 259(3):320–328. doi:10.1016/j.taap.2012.01.009